コンテンツへスキップ
Merck
  • Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis.

Plasma levels and urinary excretion of prostaglandins in patients with rheumatoid arthritis.

Clinical rheumatology (1983-12-01)
O Laitinen, E Seppalä, M Nissilä, H Vapaatalo
要旨

No significant differences were found in plasma concentrations and urinary excretion of prostaglandin E2 (PGE2), 6-keto-prostaglandin-F1 alpha (6-keto-PGF1 alpha) and thromboxane B2 (TxB2), between rheumatoid arthritis patients and controls. However, urinary excretion of PGEe and 6-keto-PGF1 alpha tended to be greater and plasma levels of TxB2 lower in rheumatoid arthritis. Plasma concentrations and urinary excretion showed no marked circadian variation, although night or morning values were slightly lower. Plasma and urine prostaglandins do not correlate with clinical symptomatology in rheumatoid arthritis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
コルチゾン, ≥95%
Sigma-Aldrich
17α-ヒドロキシプロゲステロン, ≥95%
Supelco
アンドロステンジオン 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
17α-ヒドロキシプロゲステロン 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
4-アンドロステン-3,17-ジオン, VETRANAL®, analytical standard